Navigation Links
Drug May Help Against Inflammatory Breast Cancer
Date:4/27/2009

Study shows those who respond to lapatinib survive longer,,,,

MONDAY, April 27 (HealthDay News) -- The drug lapatinib could be used to treat aggressive inflammatory breast cancer, suggest the findings of a phase 2 study.

Inflammatory breast cancer accounts for up to 6 percent of all invasive breast tumors in the United States and western Europe, according to the researchers. Symptoms include rapid onset of swelling, redness of breast skin, a pitted appearance caused by fluid under the skin of more than two-thirds of the breast, tenderness, hardening and warming of the breast.

For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in other, less aggressive breast cancers.

The study included 126 women who took 1,500 milligrams of lapatinib once a day. None of them showed a full response to the drug, but 39 percent had a partial response, the researchers reported. Median progression-free survival was 15 weeks and, at 6 months, 22 percent of the women were still progression-free.

When the researchers divided the participants into four groups, they found that median overall survival was:

  • 18.4 months for those who responded to lapatinib after previous treatment with trastuzumab
  • 14 months for those who responded to lapatinib and had no previous trastuzumab treatment
  • 8.4 months for those unresponsive to lapatinib who had previously taken trastuzumab
  • 8.2 months for those unresponsive to lapatinib who had not previously taken trastuzumab.

The study found that 92 percent of the women had at least one adverse event, including shortness of breath and fluid around the lungs. Five participants died from adverse events that were possibly treatment related, said the Israeli and U.K. researchers.

"Patients who responded to treatment with lapatinib had a longer median overall survival than did those patients who did not respond, irrespective of previous exposure to trastuzumab," the researchers wrote. "Patients exposed to previous trastuzumab treatment who experienced a response to lapatinib had the longest median overall survival. This finding confirms the clinical benefit of targeted therapy in these patients."

"Lapatinib monotherapy is potentially clinically effective in heavily pretreated patients with inflammatory breast cancer with HER2+ tumors," they said. "The objective response rate noted ... coupled with the median duration of response and median overall survival supports a role for lapatinib in these patients."

The study appears online and in the June print issue of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about inflammatory breast cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, April 26, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Despite overeating, morbidly obese mice gain protection against diabetes
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
8. $52.5 Million Settlement Against Sepracor Inc. Approved
9. The fight against colorectal cancer
10. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
11. Breastfeeding does not protect against asthma, allergies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Help Against Inflammatory Breast Cancer
(Date:2/5/2016)... ... February 05, 2016 , ... The ... Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign ... with muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... Looking ... answer may be at the tips of your toes. Foot massage, whether administered by ... as pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... US ... Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio ... seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Summary Breast cancer, a ... the most common cancer in women worldwide, accounting for ... prevalent. The number of women diagnosed with breast cancer ... number of deaths has declined due to earlier diagnosis ... been revolutionized in the past four decades, especially with ...
(Date:2/4/2016)... Ohio, Feb. 4, 2016 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year.  Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior- year period.  Adjusted EPS was $4.65, an ...
(Date:2/4/2016)... , Feb. 4, 2016  Blueprint Medicines Corporation ... and developing highly selective investigational kinase medicines for ... appointment to its board of directors of ... nearly 30 years of industry-related experience. ... Blueprint Medicines. "Lonnel,s strong strategic experience developing and ...
Breaking Medicine Technology: